[ad_1]
Operator
Okay. We’re good to go. Welcome to this Novo Nordisk fireplace on the 61st Version of EASD right here in Vienna. Welcome to all of you within the room and in addition welcome to these listening in on-line.
At the moment’s name will deal with the R&D and within the pipeline, and we’re right here immediately with Martin, who will take us by among the developments later. Earlier than we get into it, only a standard phrase of warning by way of the forward-looking statements and that the long run is unpredictable, that pertains, specifically, in terms of the pipeline.
By way of the format, Martin will spend a couple of minutes on some opening remarks. After that, we’ll flip it to you within the room the place we go round with 1 query every, and we’ll take the dialogue the place you want to go. As stated, we’ll focus the decision on the pipeline and R&D occasions, each pertaining to the EASD, but in addition to the pipeline general.
So with that, welcome, and over to you, Martin.
Martin Lange
EVP of R&D, CSO and Member of the Administration Board
Thanks very a lot. So principally, I am going to simply discuss somewhat bit in regards to the new R&D group that has been created in Novo Nordisk. As you already know, for the final
[ad_2]
